British drugmaker AstraZeneca is on a mission to lock in as many manufacturing partners as possible to support a planned global rollout for its COVID-19 vaccine front-runner. A New York CDMO has now jumped on board, and it will commit its Southwestern facility to help pick up the slack.
New York-based Albany Molecular Research will pick up fill-finish duties for “millions of doses” of AstraZeneca and the University of Oxford’s adenovirus-based COVID-19 shot at its Albuquerque, New Mexico site, the CDMO said Thursday.
Albany Molecular said it would support production of the vaccine, dubbed AZD1222, through 2021 on “unprecedented manufacturing timelines.” Financial terms of the deal were not disclosed.
Featured Webinar
Improving Patient Outcomes & Clinical Trials With Visual Analytics
Drug Development has always been about data. Research insight that comes from data often gets muddied by its vastness and inaccessibility. In this session we discuss Takeda Pharmaceutical’s Platypus, a comprehensive set of Tableau visualizations of clinical trial data. Register for this webinar to learn more.
AstraZeneca’s network of contract manufacturing partners for Oxford’s shot continues to grow with the Albany Molecular tie-up as the British drugmaker pieces together a global supply chain that aims to distribute up to 3 billion doses of AZD1222 each year.
